Home » Posts tagged 'BITTER MELON'
Tag Archives: BITTER MELON
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....FOR BLOG HOME CLICK HEREFlag and hits
ORGANIC SPECTROSCOPY
SUBSCRIBE
Subscribe in a reader
Enter your email address:
Delivered by FeedBurner
Subscribe to New Drug Approvals by Email
Recent Comments
 | shivkr2 on SPSR Excellence Award 2025 – S… |
 | Bonkasaurus on Infigratinib phosphate |
 | PALOVAROTENE | ORGAN… on Palovarotene |
| Pfizer just purchase… on Temanogrel | |
| Pfizer To Cash In On… on Temanogrel |
Bitter Melon (Momordica charantia Linn.)(fruit) Dried water extract).help steady your blood sugar levels
Helps support normal blood sugar levels with compounds called charantin and momordicin. Additional key compounds such as vicine, peptides, and polypeptide-p (plant insulin) also work together to give Bitter Melon its potency.
Bitter Melon (Momordica charantia Linn.)(fruit) Dried water extract).
The balance between the good things and bad things you eat is sometimes hard to keep steady. Bitter Melon is a natural fruit that can help steady your blood sugar levels, as it works to promote normal blood sugar levels in your body. Thus it is a reliable safety net when you need glycemic control.
Bitter Melon is different than many other herbs in that it is often eaten as a dish. Thus it is proven safe to ingest. Bitter Melon is an unique fruit with good nutritional value, which is why Health Canada recommends it on their website as a way to “Treat Your Taste Buds” (Health Canada, Feb. 2008).
Bitter Melon was studied in a randomized, double-blind, placebo-controlled trial. Before beginning the trial, 40 subjects had various chemical parameters such as fasting blood sugar, cholesterol, weight, and glycosylated HG (Alc) measured. The subjects were separated into a placebo group and a Bitter Melon group. The results of the study show that the Bitter Melon group had positive indications such as it supporting Alc. At the same time there were no negative side effects reported.
Key Benefits of Bitter Melon:
• Helps achieve normal blood sugar levels – This is mainly achieved with charantin and momordicin compounds. The effectiveness is improved with other important compounds including vicine, peptides, and polypeptide-p (plant insulin).
• Aids in keeping the level of triglycerides and cholesterol in the liver and blood within normal range.
• Promotes normal function of the immune system.
AYURVEDA- BITTER MELON (Momordica charantia)
BITTER MELON (Momordica charantia): This edible gourd should be every physician’s “go-to” plant for the 16 million or more Americans with high-normal glucose readings or ‘boderline diabetic/metabolic syndrome patients.
Preliminary evidence suggests bitter melon’s hypoglycemic action can be explained through several independent mechanisms: for one, it has been shown to increase peripheral glucose oxidation as well as glucose tolerance and insulin signaling in induced insulin resistance models (Sridhar MG, et al: Br J Nutr. 2008;99(4):806-12. Basch E, et al. Am J Health Syst Pharm. 2003;60:356-9). It also decreases hepatic gluconeogenesis, while increasing glycogen synthesis.
Bitter Melon increases insulin output from the pancreas, and it also provides a unique compound called polypeptide-P, which is an insulin mimetic with a similar structure to bovine insulin (Krawinkel MB, Keding GB. Nutr Rev. 2006;64(7 Pt 1):331-7).
Bitter Melon slices.Compounds produced by this intriguing gourd have been shown to reduce triglyceride levels in a dose-dependent manner in animal trials (Jayasooriya AP, et al. J Ethnopharmacol. 2000;72:331-6). Though we don’t yet have human data corroborating this effect, the animal studies suggest that bitter melon may have a role in reducing cardiovascular risk, particularly in people with diabetes or metabolic syndrome.
Bitter melon products are typically standardized to their constituents, momordicosides and charantin, and usually dispensed in 500-600 mg doses, twice daily, following meals. As it does have an insulin mimetic action, it may be necessary to adjust the dose of concurrently prescribed hypoglycemic drugs.
New Drug Approvals 